Measles Virus Antigen- Premium

SERION Immunologics Measles Virus Antigen - Premium was successfully applied in in-vitro stimulation assays to assess anti-tumor immunity induced by virotherapy.

Several preclinical and clinical studies have shown beneficial effects of oncolytic virotherapy to fight cancer. Release of tumor antigens by viral oncolysis lead to immune cell influx and reshaping of the tumor immune environment (Achard et al., 2018, Veinalde et al., 2023).

The German Cancer Research Center (DKFZ) Heidelberg, Germany, together with further collaboration partners, recently published new insights into systemic anti-tumor immunity induced by virotherapy (Veinalde et al., 2023).

Virion\Serion’s Measles Virus Antigen - Premium (BA102VS-S) was used in these studies for in-vitro stimulation of splenocytes isolated from a tumor mouse model to assess the elicited immune responses. Hereby, significantly increased tumor-specific IFN-γ responses and systemic anti-tumor immunity induced by virotherapy were proven.

If you have any further questions about Virion\Serion’s Measles Virus - Premium Antigen, please feel free to get in touch with us: immunologics@



Achard C, Surendran A, Wedge ME, Ungerechts G, Bell J, Ilkow CS. Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy. EBioMedicine. 2018 May;31:17-24. doi: 10.1016/j.ebiom.2018.04.020. Epub 2018 Apr 23. PMID: 29724655; PMCID: PMC6013846.

Veinalde R, Pidelaserra-Martí G, Moulin C, Tan CL, Schäfer TE, Kang N, Ball CR, Leichsenring J, Stenzinger A, Kaderali L, Jäger D, Ungerechts G, Engeland CE. Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model. Front Immunol. 2023 Jan 16;13:1096162. doi: 10.3389/fimmu.2022.1096162. PMID: 36726983; PMCID: PMC9886093.